E1	Procedure:T1 Name:T2 Temporality:E24
E3	Procedure:T3 Name:T4 Temporality:E21
E5	Condition:T5 Name:T6
E7	Condition:T7 Name:T8
E9	Procedure:T9 Name:T10 Temporality:E16
E11	Procedure:T11 Name:T12
E13	Procedure:T13 Name:T14
E17	Condition:T17 Name:T18
E18	Age:T27 Eq-Comparison:E19
E19	Eq-Comparison:T34 Operator:T19 Value:T28
E20	Eq-Comparison:T35 Operator:T20 Temporal-Unit:T23 Value:T29
E21	Eq-Comparison:T36 Operator:T21 Temporal-Unit:T24 Value:T31
E22	Eq-Comparison:T37 Operator:T22 Temporal-Unit:T25 Value:T32
E2	Or:T38 Arg:T15 Arg2:T16
E4	Condition:T26 Name:T39
E6	Assertion:T40 Asserted:E7
E8	Observation:T42 Name:T43 Eq-Comparison:E20
E10	Eq-Comparison:T44 Value:T45 Value2:T30 Operator:T46
E12	Observation:T47 Name:T48
E14	Drug:T49 Name:T50 Temporality:E15
E23	Modifier:T53 Modifies:E1
E25	Modifier:T55 Modifies:E3
E26	Temporal-Connection:T56 Arg2:E27 Arg:E21
E27	Study:T57 Study-Of:E39
E28	Condition:T58 Name:T59
E29	Procedure:T60 Name:T61 Temporality:E22
E30	Exception:T62 From:E29 Except:E11
E31	Or:T63 Arg:E22 Arg2:E41
E32	Procedure:T65
E33	Temporal-Connection:T67 Arg:E32 Arg2:E44
E34	Study:T68 Study-Of:E43
E35	Study:T69
E36	Temporal-Connection:T70 Arg:E35 Arg2:E7
E37	Observation:T71 Name:T72 Eq-Comparison:E10
E24	Eq-Comparison:T54 Temporal-Period:T73
E38	Or:T74 Arg:E1 Arg2:E3
E39	Drug:T75
E15	Eq-Comparison:T41 Temporal-Period:T51
E16	Eq-Comparison:T52 Temporal-Period:T76
E40	Modifier:T77 Modifies:T59
E41	Eq-Comparison:T78 Value:T33 Unit:T64
E42	Temporal-Connection:T79 Arg:E41 Arg2:E32
E43	Drug:T66 Temporality:E44
E44	Eq-Comparison:T80 Temporal-Recency:T81
T1	Procedure 580 600	stem cell transplant
T2	Procedure-Name 580 600	stem cell transplant
T3	Procedure 637 657	stem cell transplant
T4	Procedure-Name 637 657	stem cell transplant
T5	Condition 186 205	progressive disease
T6	Condition-Name 186 205	progressive disease
T7	Condition 147 154	disease
T8	Condition-Name 147 154	disease
T9	Procedure 502 520	CAR-T cell therapy
T10	Procedure-Name 502 520	CAR-T cell therapy
T11	Procedure 899 911	radiotherapy
T12	Procedure-Name 899 911	radiotherapy
T13	Procedure 839 846	therapy
T14	Procedure-Name 839 846	therapy
T15	Life-Stage-And-Gender 43 49	female
T16	Life-Stage-And-Gender 35 39	male
T17	Condition 207 209	PD
T18	Condition-Name 207 209	PD
T19	Eq-Operator 29 30	≥
T20	Eq-Operator 254 266	no less than
T21	Eq-Operator 658 664	within
T22	Eq-Operator 925 931	within
T23	Eq-Temporal-Unit 269 275	months
T24	Eq-Temporal-Unit 667 673	months
T25	Eq-Temporal-Unit 934 939	weeks
T27	Age 25 28	Age
T28	Eq-Value 31 33	18
T29	Eq-Value 267 268	6
T30	Eq-Value 373 374	0
T31	Eq-Value 665 666	3
T32	Eq-Value 932 933	4
T33	Eq-Value 943 944	5
T34	Eq-Comparison 29 33	≥ 18
T35	Eq-Comparison 254 275	no less than 6 months
T36	Eq-Comparison 658 673	within 3 months
T37	Eq-Comparison 925 939	within 4 weeks
T38	Or 40 42	or
T26	Condition 89 91	MM
T39	Condition-Name 89 91	MM
T40	Assertion 136 146	measurable
T42	Observation 235 250	life expectancy
T43	Observation-Name 235 250	life expectancy
T44	Eq-Comparison 373 376	0~2
T45	Eq-Value 375 376	2
T46	Eq-Operator 374 375	~
T47	Observation 303 307	ECOG
T48	Observation-Name 303 307	ECOG
T49	Drug 424 463	anti-CD38 monoclonal antibody treatment
T50	Drug-Name 424 463	anti-CD38 monoclonal antibody treatment
T53	Modifier 570 579	allogenic
T55	Modifier 626 636	autologous
T56	Temporal-Connection 674 680	before
T57	Study 703 708	study
T58	Condition 749 756	myeloma
T59	Condition-Name 749 756	myeloma
T60	Procedure 875 897	anti-myeloma treatment
T61	Procedure-Name 875 897	anti-myeloma treatment
T62	Exception 915 923	excluded
T63	Or 940 942	or
T64	Eq-Unit 945 958	PK half-lives
T65	Procedure 966 975	treatment
T67	Temporal-Connection 995 1001	before
T68	Study 1012 1017	study
T69	Study 101 110	screening
T70	Temporal-Connection 98 100	At
T71	Observation 309 343	Eastern Cooperative Oncology Group
T72	Observation-Name 309 343	Eastern Cooperative Oncology Group
T54	Eq-Comparison 550 560	previously
T73	Eq-Temporal-Period 550 560	previously
T74	Or 602 604	or
T75	Drug 709 714	agent
T41	Eq-Comparison 464 474	previously
T51	Eq-Temporal-Period 464 474	previously
T52	Eq-Comparison 521 531	previously
T76	Eq-Temporal-Period 521 531	previously
T77	Modifier 721 748	Primary refractory multiple
T78	Eq-Comparison 943 958	5 PK half-lives
T79	Temporal-Connection 959 961	of
T66	Drug 1018 1023	agent
T80	Eq-Comparison 1006 1011	first
T81	Eq-Temporal-Recency 1006 1011	first
A1	Life-Stage-And-Gender-Type T15 female
A2	Life-Stage-And-Gender-Type T16 male
A3	Eq-Operator-Value T19 GTEQ
A4	Eq-Operator-Value T20 GTEQ
A5	Eq-Operator-Value T21 LTEQ
A6	Eq-Operator-Value T22 LTEQ
A7	Eq-Temporal-Unit-Value T23 month
A8	Eq-Temporal-Unit-Value T24 month
A9	Eq-Temporal-Unit-Value T25 week
A11	Observation-Type-Value T43 vital
A12	Eq-Operator-Value T46 BETWEEN
A13	Observation-Type-Value T48 clinical-score
A17	Temporal-Connection-Type-Value E26 before
A18	Temporal-Connection-Type-Value E33 before
A19	Temporal-Connection-Type-Value E36 during
A16	Eq-Temporal-Period-Value T73 past
A21	Assertion-Type-Value E6 hypothetical
A10	Eq-Temporal-Period-Value T51 past
A14	Eq-Temporal-Period-Value T76 past
A15	Temporal-Connection-Type-Value E42 before
A20	Eq-Temporal-Recency-Value T81 first-time
R2	Abbrev-Of Arg1:E17 Arg2:E5
R3	Abbrev-Of Arg1:E37 Arg2:E12
R1	Treatment-For Arg1:E13 Arg2:E28